Therefore, suppressing TSLP seems like a reasonable strategy for preventing the progression of viral infection-related inflammation and currently tezepelumab, a human monoclonal antibody specific for TSLP, is studied for uncontrolled asthma [20,21]. Here, TSLP is linked to asthma.